Transcriptome of liver tissue in 2 week old and E17.5 Stabilin-1 knock-out mice
Ontology highlight
ABSTRACT:
ORGANISM(S): Mus musculus
PROVIDER: GSE114969 | GEO | 2018/09/14
REPOSITORIES: GEO
Similar Datasets
Project description:Stabilin-1/CLEVER-1 is a multidomain protein present in lymphatic and vascular endothelial cells and in M2 immunosuppressive macrophages. Stabilin-1 functions in scavenging, endocytosis and leukocyte adhesion to and transmigration through the endothelial cells.
2016-07-15 | GSE78752 | GEO
Project description:Stabilin-1/CLEVER-1 is a multidomain protein present in lymphatic and vascular endothelial cells and in M2 immunosuppressive macrophages. Stabilin-1 functions in scavenging, endocytosis and leukocyte adhesion to and transmigration through the endothelial cells. The transcriptome of liver tissue in 5wk old Stab1 knock-out mice was compared to that of corresponding wild type mice
2016-07-15 | E-GEOD-78752 | biostudies-arrayexpress
Project description:Stabilin-1/CLEVER-1 is a multidomain protein present in lymphatic and vascular endothelial cells and in M2 immunosuppressive macrophages. Stabilin-1 functions in scavenging, endocytosis and leukocyte adhesion to and transmigration through the endothelial cells. We have analyzed the putative functions of Stabilin-1 in blood monocytes and found that in healthy individuals 60-80% of both CD14+CD16- and CD14+C16+ monocytes, but not CD14dimCD16+ monocytes, expressed Stabilin-1 on the surface. Microarray and RNAseq analysis was performed to get more insight into the effect of Stabilin-1 expression on human monocytes transcriptome.
2015-11-30 | GSE63807 | GEO
Project description:Stabilin-1/CLEVER-1 is a multidomain protein present in lymphatic and vascular endothelial cells and in M2 immunosuppressive macrophages. Stabilin-1 functions in scavenging, endocytosis and leukocyte adhesion to and transmigration through the endothelial cells. We analyzed the putative functions of Stabilin-1 in blood monocytes. We found that in healthy individuals 60-80% of both CD14+CD16- and CD14+C16+ monocytes, but not CD14dimCD16+ monocytes, expressed Stabilin-1 on the surface. Microarray analysis was performed to study these monocytes subtypes in more detail.
2015-11-30 | GSE63519 | GEO
Project description:Stabilin-1 is a scavenger/sorting receptor expressed by sinusoidal endothelial cells, alternatively-activated and tumor-associated macrophages (TAM) in several types of human cancer and mouse tumor models. We have found abundant expression of stabilin-1 on TAM in mouse model of mammary adenocarcinoma (TS/A) We performed microarrays with TAM isolated from wild type (wt) and stabilin-1 knock out (ko) mice in order to examine if stabilin-1 affects gene expression in TAM using mouse model of TS/A mammary adenocarcinoma Balb/c Wt and stabilin-1 ko female mice (8-12 weeks old) were inoculated s.c. with 5x10e6 TS/A cells. TAM were isolated from TS/A tumors 21 days after tumor challenge using CD11b MACS beads (Miltenyi Biotec), lysed for RNA and used for microarrays. Samples from 3 wt and 3 stabilin-1 ko mice were analyzed.
2014-10-30 | E-GEOD-55595 | biostudies-arrayexpress
Project description:Stabilin-1 is a scavenger/sorting receptor expressed by sinusoidal endothelial cells, alternatively-activated and tumor-associated macrophages (TAM) in several types of human cancer and mouse tumor models. We have found abundant expression of stabilin-1 on TAM in mouse model of mammary adenocarcinoma (TS/A) We performed microarrays with TAM isolated from wild type (wt) and stabilin-1 knock out (ko) mice in order to examine if stabilin-1 affects gene expression in TAM using mouse model of TS/A mammary adenocarcinoma
2014-10-30 | GSE55595 | GEO
Project description:Transcriptome of liver tissue in 2 week old and E17.5 Stabilin-1 knock-out mice
| PRJNA473361 | ENA
Project description:Tumor resistance to chemotherapy and metastatic relapse account for more than 90% of cancer specific mortality. Tumor associated macrophages (TAMs) can process chemotherapeutic agents and impair their action. Little is known about the direct effects of chemotherapy on TAMs. Here we show that chemotherapeutic agent cisplatin can initiate detrimental transcriptional and functional programs in TAMs, without significant impairment of their viability. We focused on the clearance function of TAMs that controls composition of tumor microenvironment. For the first time we demonstrated, that TAMs scavenger receptor stabilin-1 is responsible for the clearance of EGF, a potent stimulator of tumor growth. Cisplatin suppressed both overall and EGF-specific endocytosis in TAMs by bidirectional mode: suppression of positive regulators and stimulation of negative regulators of endocytosis, with strongest effect on SYT11, confirmed in patients with breast cancer. Our data demonstrate that synergistic action of cytostatic agents and innovative immunomodulators is required to overcome cancer therapy resistance.
2023-02-10 | GSE224681 | GEO
Project description:Long term use of titanium implants generates wearing particles off. Titanium nanoparticles (TiNP) favor a pro-inflammatory macrophage polarization (M1) and lower the tolerogenic activation (M2). Our previous Affymetrix data showed that TiNP upregulate GDF15 and downregulate STAB1 expression in macrophages. GDF15 is a cytokine that regulates energy expenditure and fibrosis, and is endocytosed by the scavenger receptor Stabilin-1. Our study aim was to investigate the effect of TiNP on GDF15 and STAB1 expression, on GDF15 secretion and on endocytosis efficiency in macrophages. We used the model system of primary human macrophages derived from CD14+ monocytes. After 6 days of incubation with TiNP, we quantified GDF15 and STAB1 expression, and GDF15 secretion in INF-γ stimulated (M1) and IL-4 stimulated (M2) macrophages using RT-PCR and ELISA, respectively. Flow cytometry assessed the effect of TiNP on endocytosis based on the uptake of fluorescently labelled acLDL, a known ligand of stabilin-1, and MS-1, an antibody directed against the extracellular portion of stabilin-1 in M1 and M2. Our results revealed a strong up-modulating effect of TiNP on GDF15 expression and secretion in all subtypes of macrophages. In contrast, stabilin-1 expression was significantly suppressed by TiNP. acLDL and MS-1 uptake by macrophages was also significantly suppressed under the treatment with TiNP. Our findings highlight a consistent ex vivo stimulatory effect of TiNP on GDF15 production and inhibitory effect on STAB1 expression and Stabilin-1-mediated endocytosis. Our results suggest an important implication of TiNP on macrophage healing functions.
2022-01-05 | GSE179543 | GEO
Project description:Macrophages are critical in driving an immunosuppressive tumour microenvironment that counteracts the efficacy of T-cell targeting therapies1. Thus agents, which can re-programme macrophages towards a pro-inflammatory state hold promise as novel immunotherapies for solid cancers2. Here we report that therapeutic targeting of a macrophage scavenger receptor, Clever-13, in heavily pre-treated metastatic cancer patients was able to induce a significant increase and activation of peripheral T-cells including downregulation of several immune checkpoint molecules. Transcriptional and mass cytometry analyses revealed treatment induced inflammatory conversion of blood monocytes, which was partly driven by impaired Clever-1 mediated scavenging. Identification of relevant peripheral signatures indicative of anti-tumour activity showed induction of an effector CD8 T-cell population that resulted from clonal expansion of cytotoxic CD8 T-cells. In some patients this was accompanied by features of increased accumulation of CD8 T-cells in post-treatment tumour biopsies. Our results reveal a non-redundant role played by the receptor Clever-1 in suppressing adaptive immune cell activation in humans. We provide evidence that targeting macrophage scavenging activity can promote an immune switch leading to peripheral activation and potentially intra tumoural proinflammatory responses in metastatic cancer patients. Anti-Clever-1 treatment may therefore provide an attractive immunotherapeutic strategy in cancer.
2022-05-22 | GSE152169 | GEO